Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replicel Life Sciences Inc
(TSV:
RP
)
0.0150
-0.0050 (-25.00%)
Streaming Delayed Price
Updated: 12:10 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Replicel Life Sciences Inc
< Previous
1
2
Next >
RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities
December 14, 2023
From
RealPage, Inc.
Via
Business Wire
RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite
November 15, 2023
From
RealPage, Inc.
Via
Business Wire
RealPage Unveils New Multifamily Rental Trends
August 08, 2023
From
RealPage
Via
Business Wire
RepliCel Provides Corporate Update
November 28, 2022
Via
ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
August 04, 2022
Via
ACCESSWIRE
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence
March 28, 2023
From
RealPage
Via
Business Wire
Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments
December 09, 2022
Curaleaf Names Director Of Social Equity
Via
Benzinga
Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development
August 18, 2022
A joint venture between two Fundrise-sponsored funds has led to the acquisition of 18 rental homes in the Ridgeview Villas community in Allen, Texas, north of Dallas.
Via
Benzinga
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
August 02, 2022
Via
ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Material Patent Milestones
January 10, 2022
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
December 21, 2021
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Terminates License Agreement with Shiseido
December 21, 2021
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry
December 07, 2021
From
RealPage, Inc.
Via
Business Wire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
November 11, 2021
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
November 09, 2021
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc....
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
October 28, 2021
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Dermal Injector Update
October 27, 2021
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
October 18, 2021
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
October 12, 2021
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Economy
Exposures
Economy
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
September 16, 2021
- Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
RealPage To Acquire G5, Leader in Real Estate Marketing Optimization
July 20, 2021
From
RealPage, Inc.
Via
Business Wire
RealPage Announces New Prepaid Debit Card Solution
July 13, 2021
From
RealPage, Inc.
Via
Business Wire
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
July 07, 2021
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RealPage Launches Revolutionary Water Management Solution: Smart Water
July 06, 2021
From
RealPage, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.